Related Articles
Pristimerin, a quinonemethide triterpenoid, induces apoptosis in pancreatic cancer cells through the inhibition of pro-survival Akt/NF-κB/mTOR signaling proteins and anti-apoptotic Bcl-2
Inhibition of hTERT/telomerase contributes to the antitumor activity of pristimerin in pancreatic ductal adenocarcinoma cells
CDDO-Me inhibits tumor growth and prevents recurrence of pancreatic ductal adenocarcinoma
PHLPP2 is a novel biomarker and epigenetic target for the treatment of vitamin C in pancreatic cancer
Inhibition of hTERT in pancreatic cancer cells by pristimerin involves suppression of epigenetic regulators of gene transcription